Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
T-cell targeted immunotherapy against the tumor associate... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.
0
Authors
Scott Burkholz
4 more
Scott Burkholz
•
C.v. Herst
2 more
•
Reid Rubsamen
Published
July 25, 2022
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Medicine
Immunology
Internal Medicine
Show all topics
DOI
10.1101/2022.07.25.501455
License
CC-BY-NC
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Medicine
Immunology
Internal Medicine
Show all topics
DOI
10.1101/2022.07.25.501455
License
CC-BY-NC
Other Formats
PDF
